The development of innovative
and medical technologies
To drive the development and clinical application of innovative by
leveraging RIKEN’s rich life science research infrastructure
News & Topics
Immune response to seasonal coronaviruses may offer protection against COVID-19
RIKEN Research Cluster for Innovation Drug Discovery and Medical Technology Platforms has arranged a new setup（Program Director OKAZAKI Hiroshi）
Completion of the first patient treatment for cancer immunotherapy with iPS-NKT cells (Japanese only)
Report was published "Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function"
"Safety Study of allogenic hiPSC-retinas in Retinitis Pigmentosa (hiRERP)"---the surgery was conducted on the first patient at Kobe eye center hospital." (Japanese only)
One of the Drug Discovery Chemistry Platform Unit's paper was featured in the Journal of Medicinal Chemistry Virtual Issue which features 15 articles published during 2017-2019 showcasing outstanding medicinal chemistry research from Japan. Title of paper: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer
RIKEN and Lynk Pharmaceuticals enter into exclusive licensing agreement (Japanese only)
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19) (Japanese only)
RIKEN DMP launches special project to combat COVID-19
The business development office handles alliances for collaboration with companies, universities, and external research institutes. It is also involved in licensing intellectual property rights to companies in collaboration with RIKEN Innovation.